Literature DB >> 16294340

A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors.

Jean-Sebastien Surgand1, Jordi Rodrigo, Esther Kellenberger, Didier Rognan.   

Abstract

The amino acid sequences of 369 human nonolfactory G-protein-coupled receptors (GPCRs) have been aligned at the seven transmembrane domain (TM) and used to extract the nature of 30 critical residues supposed--from the X-ray structure of bovine rhodopsin bound to retinal--to line the TM binding cavity of ground-state receptors. Interestingly, the clustering of human GPCRs from these 30 residues mirrors the recently described phylogenetic tree of full-sequence human GPCRs (Fredriksson et al., Mol Pharmacol 2003;63:1256-1272) with few exceptions. A TM cavity could be found for all investigated GPCRs with physicochemical properties matching that of their cognate ligands. The current approach allows a very fast comparison of most human GPCRs from the focused perspective of the predicted TM cavity and permits to easily detect key residues that drive ligand selectivity or promiscuity. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16294340     DOI: 10.1002/prot.20768

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  62 in total

1.  Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.

Authors:  Carl Högberg; Olof Gidlöf; Francesca Deflorian; Kenneth A Jacobson; Aliaa Abdelrahman; Christa E Müller; Björn Olde; David Erlinge
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

2.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.

Authors:  Chris de Graaf; Albert J Kooistra; Henry F Vischer; Vsevolod Katritch; Martien Kuijer; Mitsunori Shiroishi; So Iwata; Tatsuro Shimamura; Raymond C Stevens; Iwan J P de Esch; Rob Leurs
Journal:  J Med Chem       Date:  2011-11-07       Impact factor: 7.446

Review 3.  Chemogenomic approaches to rational drug design.

Authors:  D Rognan
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

4.  Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA(4)/p2y(9)/GPR23 receptor: a homology modeling study.

Authors:  Guo Li; Philip D Mosier; Xianjun Fang; Yan Zhang
Journal:  J Mol Graph Model       Date:  2009-04-19       Impact factor: 2.518

5.  An indel in transmembrane helix 2 helps to trace the molecular evolution of class A G-protein-coupled receptors.

Authors:  Julie Devillé; Julien Rey; Marie Chabbert
Journal:  J Mol Evol       Date:  2009-04-09       Impact factor: 2.395

6.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 7.  Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects.

Authors:  Stefano Costanzi; Susanne Neumann; Marvin C Gershengorn
Journal:  J Biol Chem       Date:  2008-04-02       Impact factor: 5.157

8.  GPR88 - a putative signaling molecule predominantly expressed in the striatum: Cellular localization and developmental regulation.

Authors:  Vincent Van Waes; Kuei Y Tseng; Heinz Steiner
Journal:  Basal Ganglia       Date:  2011-07-01

Review 9.  G protein-coupled receptors--recent advances.

Authors:  Dorota Latek; Anna Modzelewska; Bartosz Trzaskowski; Krzysztof Palczewski; Sławomir Filipek
Journal:  Acta Biochim Pol       Date:  2012-12-18       Impact factor: 2.149

10.  Design, Synthesis, and Structure-Activity Relationship Studies of (4-Alkoxyphenyl)glycinamides and Bioisosteric 1,3,4-Oxadiazoles as GPR88 Agonists.

Authors:  Md Toufiqur Rahman; Ann M Decker; Tiffany L Langston; Kelly M Mathews; Lucas Laudermilk; Rangan Maitra; Weiya Ma; Emmanuel Darcq; Brigitte L Kieffer; Chunyang Jin
Journal:  J Med Chem       Date:  2020-11-18       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.